The Non-Alcoholic Fatty Liver Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Non-Alcoholic Fatty Liver Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Alcoholic Fatty Liver Disease Market.

Some of the key takeaways from the Non-Alcoholic Fatty Liver Disease Pipeline Report:

Companies across the globe are diligently working toward developing novel Non-Alcoholic Fatty Liver Disease treatment therapies with a considerable amount of success over the years. 
Non-Alcoholic Fatty Liver Disease companies working in the treatment market are SCOHIA PHARMA, Albireo Pharma, Redx Pharma, JD Bioscience Inc, Hepanova, Boston Pharmaceuticals, Sagimet Biosciences Inc., Dr. Falk Pharma GmbH, Viking Therapeutics, Galectin Therapeutics, AstraZeneca, Cirius Therapeutics, PharmaKing, Madrigal Pharmaceuticals, and others, are developing therapies for the Non-Alcoholic Fatty Liver Disease treatment 

Emerging Non-Alcoholic Fatty Liver Disease therapies in the different phases of clinical trials are- SCO 116, A 3907, RXC 007, GM 60106, HPN 01, BOS-580, TVB-2640, ZED 1227, VK 2809, Belapectin, Cotadutide, MSDC-0602K, Oltipraz, Resmetirom, and others are expected to have a significant impact on the Non-Alcoholic Fatty Liver Disease market in the coming years.  
In September 2022, If lanifibranor is approved, Inventiva and Chia Tai-Tianqing Pharmaceutical Group will work together to develop and market it in mainland China, Hong Kong, Macau, and Taiwan for the treatment of nonalcoholic steatohepatitis and possibly other metabolic diseases.
In May 2022, Hepion Pharmaceuticals and HepQuant, a privately held firm with headquarters in Denver with innovative, unique investigational technology for assessing liver function and health in patients with chronic liver disorders, have collaborated clinically. Beginning in Q3 of this year, Hepion will include the HepQuant ”SHUNT” test in a specialised Phase IIb clinical trial in people with suspected NASH F3.
In August 2022, “A Randomised Double-Blind Placebocontrolled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver-Related Outcomes in Patients With Well-Compensated (Child-Pugh A) Non-Alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO-NASH OUTCOMES)” is the name of the study that Madrigal Pharmaceuticals, Inc. started.
In July 2022, An experiment by AstraZeneca with the working title “A Phase IIb/III Randomised, Double-blind, Placebo-controlledStudy to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis with Fibrosis” was started.
In January 2022, In order to discover novel medications for uncommon liver illnesses, LISCure Biosciences and the Mayo Clinic have agreed into a research collaboration agreement. 
In July 2021, “A 52-Week, Phase III, Open-Label Extension Study, With a Single-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients with Non-alcoholicFatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)” was the name of the trial that Madrigal Pharmaceuticals, Inc. started.

Non-Alcoholic Fatty Liver Disease Overview

A variety of conditions that are characterised by evidence of hepatic steatosis on imaging or histology (macro-vesicular steatosis) and the absence of secondary causes of hepatic steatosis, such as significant alcohol consumption, chronic use of medications that can cause hepatic steatosis, or hereditary disorders, are collectively referred to as non-alcoholic fatty liver disease (NAFLD).

Get a Free Sample PDF Report to know more about Non-Alcoholic Fatty Liver Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight

Emerging Non-Alcoholic Fatty Liver Disease Drugs Under Different Phases of Clinical Development Include:

SCO 116: SCOHIA PHARMA
A 3907: Albireo Pharma
RXC 007: Redx Pharma
GM 60106: JD Bioscience Inc
HPN 01: Hepanova
BOS-580: Boston Pharmaceuticals
TVB-2640: Sagimet Biosciences Inc.
ZED 1227: Dr. Falk Pharma GmbH
VK 2809: Viking Therapeutics
Belapectin: Galectin Therapeutics
Cotadutide: AstraZeneca
MSDC-0602K: Cirius Therapeutics
Oltipraz: PharmaKing
Resmetirom: Madrigal Pharmaceuticals
Lanifibranor: Inventiva Pharma
ALS-L1023: AngioLab
MN-001: MediciNova

Non-Alcoholic Fatty Liver Disease Route of Administration

Non-Alcoholic Fatty Liver Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Non-Alcoholic Fatty Liver Disease Molecule Type

Non-Alcoholic Fatty Liver Disease Products have been categorized under various Molecule types, such as

Oligonucleotide
Peptide
Small molecule

Non-Alcoholic Fatty Liver Disease Pipeline Therapeutics Assessment

Non-Alcoholic Fatty Liver Disease Assessment by Product Type
Non-Alcoholic Fatty Liver Disease By Stage and Product Type
Non-Alcoholic Fatty Liver Disease Assessment by Route of Administration
Non-Alcoholic Fatty Liver Disease By Stage and Route of Administration
Non-Alcoholic Fatty Liver Disease Assessment by Molecule Type
Non-Alcoholic Fatty Liver Disease by Stage and Molecule Type

DelveInsight’s Non-Alcoholic Fatty Liver Disease Report covers around 160+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Non-Alcoholic Fatty Liver Disease product details are provided in the report. Download the Non-Alcoholic Fatty Liver Disease pipeline report to learn more about the emerging Non-Alcoholic Fatty Liver Disease therapies

Some of the key companies in the Non-Alcoholic Fatty Liver Disease Therapeutics Market include:

Key companies developing therapies for Non-Alcoholic Fatty Liver Disease are – 

Non-Alcoholic Fatty Liver Disease Pipeline Analysis:

The Non-Alcoholic Fatty Liver Disease pipeline report provides insights into 

The report provides detailed insights about companies that are developing therapies for the treatment of Non-Alcoholic Fatty Liver Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Alcoholic Fatty Liver Disease Treatment.
Non-Alcoholic Fatty Liver Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Non-Alcoholic Fatty Liver Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Alcoholic Fatty Liver Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non-Alcoholic Fatty Liver Disease drugs and therapies

Non-Alcoholic Fatty Liver Disease Pipeline Market Drivers

Rise in prevalence of NAFLD, large number of drugs are currently being evaluated, growing Research and Development Activities are some of the important factors that are fueling the Non-Alcoholic Fatty Liver Disease Market.

Non-Alcoholic Fatty Liver Disease Pipeline Market Barriers

However, lack of effective strategies for the prevention and effective treatment of NAFLD, relying on biopsies makes NASH diagnosis a difficult task and other factors are creating obstacles in the Non-Alcoholic Fatty Liver Disease Market growth.

Scope of Non-Alcoholic Fatty Liver Disease Pipeline Drug Insight    

Coverage: Global
Key Non-Alcoholic Fatty Liver Disease Companies: SCOHIA PHARMA, Albireo Pharma, Redx Pharma, JD Bioscience Inc, Hepanova, Boston Pharmaceuticals, Sagimet Biosciences Inc., Dr. Falk Pharma GmbH, Viking Therapeutics, Galectin Therapeutics, AstraZeneca, Cirius Therapeutics, PharmaKing, Madrigal Pharmaceuticals, and others
Key Non-Alcoholic Fatty Liver Disease Therapies: SCO 116, A 3907, RXC 007, GM 60106, HPN 01, BOS-580, TVB-2640, ZED 1227, VK 2809, Belapectin, Cotadutide, MSDC-0602K, Oltipraz, Resmetirom, and others
Non-Alcoholic Fatty Liver Disease Therapeutic Assessment: Non-Alcoholic Fatty Liver Disease current marketed and Non-Alcoholic Fatty Liver Disease emerging therapies
Non-Alcoholic Fatty Liver Disease Market Dynamics: Non-Alcoholic Fatty Liver Disease market drivers and Non-Alcoholic Fatty Liver Disease market barriers 

Request for Sample PDF Report for Non-Alcoholic Fatty Liver Disease Pipeline Assessment and clinical trials

Table of Contents

1. Non-Alcoholic Fatty Liver Disease Report Introduction

2. Non-Alcoholic Fatty Liver Disease Executive Summary

3. Non-Alcoholic Fatty Liver Disease Overview

4. Non-Alcoholic Fatty Liver Disease- Analytical Perspective In-depth Commercial Assessment

5. Non-Alcoholic Fatty Liver Disease Pipeline Therapeutics

6. Non-Alcoholic Fatty Liver Disease Late Stage Products (Phase II/III)

7. Non-Alcoholic Fatty Liver Disease Mid Stage Products (Phase II)

8. Non-Alcoholic Fatty Liver Disease Early Stage Products (Phase I)

9. Non-Alcoholic Fatty Liver Disease Preclinical Stage Products

10. Non-Alcoholic Fatty Liver Disease Therapeutics Assessment

11. Non-Alcoholic Fatty Liver Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Non-Alcoholic Fatty Liver Disease Key Companies

14. Non-Alcoholic Fatty Liver Disease Key Products

15. Non-Alcoholic Fatty Liver Disease Unmet Needs

16 . Non-Alcoholic Fatty Liver Disease Market Drivers and Barriers

17. Non-Alcoholic Fatty Liver Disease Future Perspectives and Conclusion

18. Non-Alcoholic Fatty Liver Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services